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Abstract
Background
MER receptor tyrosine kinase (MERTK) is expressed in a variety of malignancies, including
glioblastoma multiforme (GBM). Our previous work demonstrated that inhibition of MERTK
using RNA interference induced cell death and chemosensitivity in GBM cells, implicating
MERTK as a potential therapeutic target. Here we investigate whether a novel MERTK-
selective small molecule tyrosine kinase inhibitor, UNC2025, has similar anti-tumor effects
in GBM cell lines.
Methods
Correlations between expression of GAS6, a MERTK ligand, and prognosis were deter-
mined using data from the TCGA database. GBM cell lines (A172, SF188, U251) were
treated in vitro with increasing doses of UNC2025 (50-400nM). Cell count and viability were
determined by trypan blue exclusion. Cell cycle profiles and induction of apoptosis were
assessed by flow cytometric analysis after BrdU or Po-Pro-1/propidium iodide staining,
respectively. Polyploidy was detected by propidium iodide staining and metaphase spread.
Cellular senescence was determined by β-galactosidase staining and senescence-associ-
ated secretory cytokine analysis.
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Results
Decreased overall survival significantly correlated with high levels of GAS6 expression in
GBM, highlighting the importance of TAM kinase signaling in GBM tumorigenesis and/or
therapy resistance and providing strong rationale for targeting these pathways in the clinic.
All three GBM cell lines exhibited dose dependent reductions in cell number and colony for-
mation (>90% at 200nM) after treatment with UNC2025. Cell cycle analysis demonstrated
accumulation of cells in the G2/M phase and development of polyploidy. After extended
exposure, 60–80% of cells underwent apoptosis. The majority of surviving cells (65–95%)
were senescent and did not recover after drug removal. Thus, UNC2025 mediates anti-
tumor activity in GBM by multiple mechanisms.
Conclusions
The findings described here provide further evidence of oncogenic roles for MERTK in
GBM, demonstrate the importance of kinase activity for MERTK tumorigenicity and validate
UNC2025, a novel MERTK inhibitor, as a potential therapeutic agent for treatment of GBM.
Introduction
Glioblastomamultiforme (GBM) is the most common CNS tumor in adults [1]. Patients diag-
nosed with GBM have a poor prognosis with median survival of ~14 months and a five-year
survival rate of less than five percent, even when high dose chemotherapy and radiation are
administered. The current standard of care is surgical resection followed by radiation and
administration of temozolomide on a cyclic schedule [2]. Genomic analyses of resectedGBM
patient samples are being used to elucidate subgroups and identify abnormal protein and RNA
signatures which could serve as novel therapeutic targets for this dismal disease [3, 4]. Several
protein targets with the highest expression or most frequent mutations are currently being vali-
dated as therapeutic targets and many newly developed or repurposed targeted agents are
being evaluated for in preclinical models. If successful, these agents could be moved forward
into clinical trials for patients harboring tumors with specific tumor associated or tumor spe-
cific antigens, such as EGFR and EGFR variant III, respectively [5].
There are 58 previously described receptor tyrosine kinases (RTKs), transmembrane pro-
teins that are stimulated by extracellular ligands and activate intracellular pathways. A few of
these RTKs have amplified, aberrant, or ectopic expression in GBM tumors, including EGFR,
VEGFR, and MERTK [6–8]. MERTK, a member of the TAM family of RTKs, is expressed in
~90% of GBM tumor samples and the majority of GBM cell lines [7]. MERTK is also expressed
in other malignancies, including leukemia,melanoma, and non-small cell lung cancer, and
mediates activation of proliferative and survival pathways in malignant cells [9–11]. Genetic
inhibition of MERTK using small hairpin RNA (shRNA) or small interfering RNA (siRNA)
resulted in delayed tumor development, decreased tumor cell proliferation, and induction of
apoptosis in GBM and other cancers [7, 12–14]. These data provide rationale for the develop-
ment of translatable small molecule inhibitors directed against MERTK.
Toward this end, we developedUNC2025, a novel small molecule inhibitor that potently
and selectively targets MERTK relative to other TAM family kinases (TYRO3 and AXL) and
does not significantly inhibit PDGF, MET or VEGF receptors [15]. UNC2025 is an ATP
competitive class I inhibitor with a Ki for MERTK of ~160 pM. UNC2025 blocksMERTK
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phosphorylation in cells with an IC50 of 2.6 nM, thereby preventing MERTK activation and
downstream intracellular signaling. UNC2025 is highly soluble in normal saline and has favor-
able pharmacokinetic properties in mice [15]. Preclinical evaluation of this compound in non-
small cell lung cancer models demonstrated a 50% reduction in tumor cell survival and at
300nM dose abrogates colony formation [16]. Here we evaluated the effects of treatment with
UNC2025 in both adult and pediatric GBM cell lines.
Materials and Methods
RNA analysis
Level 3 RNAseqV2 data for GlioblastomaMultiforme (GBM) was downloaded from the
TCGA data portal. Only patient tumor samples with available clinical and RNAseqV2 expres-
sion were analyzed. The gene expression data was log2 transformed and quartile cut-points
were applied to compare low (less than first quartile; lower 25%), moderate (greater than equal
to first quartile and less than equal to third quartile, middle 50%) and high (greater than third
quartile, higher 75%) expression profiles of brain tumor samples for the GAS6 gene. Log rank
test was used to compare overall survival (OS) between the three categories. Pairwise compari-
sons of OS between categories was done and the adjusted p-values were reported based on the
Tukey’s studentized range test. Hazard ratios were calculated using Cox proportional-hazards
model and the low expression category as the reference. Pairwise correlation analyses were per-
formed for genes of interest. Survival Analysis and correlation graphs were generated using
SAS 9.4 software.
Cell lines
Adult GBM cell lines U251 and A172 were obtained from American Type Culture Collection
(Manassas, VA). Pediatric GBM cell line, SF188, was obtained from UCSF Brain Tumor Bank.
Cell lines were maintained in Cellgro1 Dulbecco’s Modification of Eagle’s Medium (DMEM)
plus 10% fetal bovine serum (standard medium).
Pharmacologic agents
Lomustine (CCNU), temozolomide and cisplatin were purchased from Sigma-Aldrich1
(Sigma Aldrich Corp., St. Louis,MO). Each was reconstituted in dimethyl sulfoxide and stored
at -80°C until use. UNC2025, a MerTK tyrosine kinase inhibitor, was synthesized at the Uni-
versity of North Carolina, Chapel Hill as previously described [15]. UNC2025 was reconsti-
tuted in dimethyl sulfoxide (DMSO), aliquoted and stored at -80°C until use. UNC2369, a
tyrosine kinase inhibitor (TKI) with similar structure to UNC2025 that lacks potent MERTK
inhibitory activity (IC50 = 490nM in enzymatic assays versus 0.74nM for UNC2025), was used
as a negative control compound.
Protein lysates and western blotting
Cells were treated with described reagents for the indicated times, then harvested and sus-
pended in lysis buffer (50 mMHEPES, pH 7.5, 150 nMNaCl, 10 mM EDTA, 10% glycerol, 1%
Triton X-100, 1 mMNa3VO4, 0.1 mMNa2MoO4) with protease inhibitor (Complete Mini,
RocheMolecular Biochemicals,Mannheim, Germany) by vortexing. Lysates were incubated
on ice for 15 minutes, then centrifuged at 6000rpm for three minutes in a microfuge. Superna-
tant was collected and stored at -80°C until western blotting. Protein concentrations were
determined using the Pierce 660nm Protein Assay (Thermo Fisher Scientific, Rockford, IL).
Proteins were resolved by SDS polyacrylamide gel electrophoresis (SDS-PAGE) using the
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XCell SureLock™Mini-Cell Electrophoresis System with Novex1 protein gels. The resolved
proteins were transferred to nitrocellulosemembranes using the iBlot1 dry blotting system
(Invitrogen, Carlsbad, CA). Proteins were detected by immunoblot with the following antibod-
ies purchased from Cell Signaling Technology: (phospho-HH3 cat# 9701, Histone H3 cat#
9715, p21 cat# 2947, PARP cat# 9542, phospho-AURKB cat# 3094, AURKB cat# 2914, and α-
tubulin cat# 2144). MERTK (cat# ab52968) and TYRO-3 antibodies (cat# ab37841) were pur-
chased from Abcam, and the AXL antibody (cat# AF154) was purchased from R&D.
Immunoprecipitation
Cells (3 x 106 per sample) were treated with UNC2025 for one hour and 1mM pervanadate was
added to the medium for the last five minutes. Cells were harvested and cell lysates were pre-
pared as described above. Lysates were incubated with 3.6ug of MerTK antibody (R&D cat #
MAB8912) for 10 minutes and then 25uL of a 50% slurry of recombinant Protein G- Sephar-
ose1 beads was added and samples were incubated at 4°C on a rotator overnight. The next day
samples were washed and suspended in 2x Laemmli sample buffer, then analyzed by immuno-
blotting as described above. Membranes were probed with anti-phosphorylatedMERTK anti-
body [16], then bound antibodies were removed frommembranes with stripping buffer (H20,
10% SDS, TRIS, β-mercaptoethanol) and membranes were probed with anti-human MERTK
antibody (Abcam cat # ab52968). Phosphorylated and total MERTK were quantitated by densi-
tometry using Image J software [17].
Surface MERTK expression
GBM cells were treated with lomustine, cisplatin or temozolomide for 48 hours. Cells were har-
vested by incubation in 0.2% EDTA for 20 minutes, then washed with phosphate buffered
saline + 2% fetal bovine serum (wash buffer) and blocked for 5 minutes in phosphate buffered
saline + 5% fetal bovine serum.Cells were then incubated with anti-human MERTK antibody
(hMer 590) [18] for 30 minutes, washed, and then incubated with Allophycocyanin-AffiniPure
F(ab')2 Fragment Donkey Anti-Mouse IgG (Jackson Immuno Research,West Grove, PA, cat #
715-136-150) for 30 minutes. Samples were again washed, centrifuged, and resuspended in
wash buffer prior to analysis on a Gallios 561 flow cytometer.
Cell count assay
GBM cell lines were cultured in medium containing 50nM, 100nM, or 200nMUNC2025, or
DMSO (vehicle control) for 120 hours, then harvested with 0.25% trypsin and 0.1% EDTA in
HBSS (cat # MT-25-053-Cl) purchased from VWR (Radnor, Pennsylvania) and resuspended
in 500uL of serum freemedium. Cells were then diluted 1:1 in 0.2% trypan blue and counted
in duplicate using a Roche CedexXS Analyzer. To analyze the recovery of cells after drug
removal, mediumwas aspirated from UNC2025 treated cell cultures and fresh mediumwith or
without UNC2025 was applied, and the cultures were incubated for an additional seven days
prior to counting as described above.
Markers of Cellular Senescence
Cells were cultured in a 24-well plate overnight in standard culture medium and then treated
with 50nM, 100nM, or 200nMUNC2025 or DMSO for an additional 120 hours. Medium was
aspirated and cells were washed, fixed, and stained using a β –Galactosidase Staining Kit (cat #
9860) purchased from Cell Signaling (Danvers, Massachusetts). Cells were observed, photo-
graphed, and counted at 400x magnification using a microscope. Approximately one hundred
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cells were counted per well; when there were fewer than 100 cells per well all cells (mini-
mum = 26) were counted. For assessment of senescence-associatedsecretory factors, GBM
cells were cultured in FBS supplemented mediumwith UNC2025 or vehicle for 72 hours.
Media were collected and stored at -80°C until use. IL-6 and IL-8 was measured using Quanti-
kine human IL-6 and IL-8 ELISAs (R&D Systems, Minneapolis, MN) per manufacturer
instructions.
Cell Cycle analysis
GBM cells were cultured in a 6-well plate overnight. Next day cells were treated with UNC2025
or DMSO for 24, 48, and 72 hours. BD Biosciences (San Jose, California) FITC BrdU Flow kit
(cat # 559619) was used for analysis. BrdU (10 uM) was added to culture medium and cells
were incubated for an additional 4 hours, then harvested with 0.25% trypsin and 0.1% EDTA
in HBSS and fixed and stained according to the protocol provided by the BD Biosciences FITC
BrdU Flow kit and analysized on a Gallios 561 flow cytometer. Analysis was performed using
Kaluza Software.
Flow Cytometric Analysis of Po-Pro-1/ Propidium Iodide Incorporation
GBM cells were cultured in medium containing UNC2025 or vehicle for 24, 48 and 72 hours,
then harvested with 0.2% EDTA in phosphate buffered saline. Cells were collected by centrifu-
gation and resuspended in PBS containing 2%FBS, 1uM Po-Pro-1 iodide, and 1ug/mL propi-
dium iodide. Fluorescence was measured using a Gallios 561 flow cytometer. Analysis was
performed using Kaluza software.
Clonogenic Assays
Five hundred cells were cultured overnight in standard medium. The next day mediumwas
aspirated and fresh medium containing UNC2025, DMSO, and/or a chemotherapeutic agent
was added. After 9 days, the mediumwas aspirated, and the plates were washed with PBS and
then stained with 0.5% crystal violet in 25% ethanol. Colonies were counted using a GelCount
colony counter (Oxford Optronix, Oxford, UK).
Results
High levels of GAS6 expression are associated with poor prognosis in
glioblastoma
We and others previously demonstrated co-expression ofMERTK and AXL,MERTK and
GAS6 (a TAM kinase ligand [19]), and AXL and GAS6 in tumor biopsies from pediatric
patients with glioblastomamultiforme [7, 20]. Here we recapitulated these results using sam-
ples from adult patients with GBM from the TCGA database, providing independent confirma-
tion of our previous data and suggesting similar roles for TAM kinase signaling in pediatric
and adult GBMs (S1 Fig). The observed co-expression of multiple TAM signaling pathways
suggests that dysregulation of non-redundant TAM signaling functions are important for
tumorigenesis in GBM. This line of reasoning led us to investigate the relationship between
GAS6 expression, which would be expected to impact signaling through bothMERTK and
AXL, and tumor progression in GBM using the TCGA database. Patients were divided into
quartiles based on GAS6 transcript levels and assigned to groups with low (lowest quartile),
moderate (middle quartiles) and high (top quartile)GAS6 expression. In these studies, patients
with high levels of GAS6 expression had significantly reducedmedian survival relative to those
with low levels of GAS6 (343 days post-diagnosis versus 448 days, respectively; p = 0.0110)
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with a hazard ratio of 2.02 (1.17–3.51 95% CI, p = 0.012) (Fig 1). These data provide evidence
of an important role for TAM kinase signaling in GBM tumorigenesis and therapy resistance.
UNC2025 inhibits MERTK activation and reduces clonal expansion,
colony-forming potential, and neurosphere diameter in glioblastoma
cells
We have previously demonstrated that MERTK activates migratory, survival, and proliferative
pathways and is critical to GBM tumor growth [7]. the recent development of UNC2025, a
highly potent MERTK ATP-competitive type 1 inhibitor, provides a novel and translatable
approach to blockMERTK activation and test effects on critical malignant phenotypes [15]. To
determine the ability of UNC2025 to blockMERTK activation in GBM cells, phosphorylation
of MERTK was assessed in adult GBM cell lines A172 and U251 and pediatric GBM cell line
SF188. After one hour of UNC2025 treatment, MERTK phosphorylation was reduced in all
three cell lines and in a dose dependent manner (Fig 2A and 2B).
We have previously reported that reduction of MERTK protein levels following stable trans-
duction with shRNA in the G12 and A172 GBM cell lines reduced colony formation in a soft
agar anchorage independent colony forming assay [7]. To determine if UNC2025 mediates a
similar phenotypic effect,multiple assays were utilized. First, the relative number of viable cells
was determined after five days of treatment with UNC2025 (50nM, 100nM, 200nM) or vehicle
(DMSO). In all three GBM cell lines, treatment with UNC2025 significantly reduced the num-
ber of viable cells (Fig 2C). The reduction in cell number was dose dependent and the maxi-
mum dose of 200nMUNC2025 reduced cell number by 80–98% compared to the vehicle
control (DMSO).
To further assess the impact of UNC2025 treatment on GBM cells, equal numbers of
sparsely plated GBM cells were treated with UNC2025 (50nM, 100nM, 200nM) or vehicle
(DMSO) for nine days and colony number was determined. Treatment with UNC2025 reduced
colony formation in a dose dependent manner in all three cell lines (Fig 2D). At the dose of
100nM, UNC2025 colony number was significantly decreased by 60–90% (Fig 2D), with A172
having the largest reduction. Of note, 200nMUNC2025 treatment completely blocked colony
formation in all three cell lines. These data demonstrate reduced anchorage-dependent growth
and thereby provide evidence of reduced self-renewal of GBM cells mediated by UNC2025.
Relative to two-dimensional cultures, neurosphere formation more closely recapitulates
development of a tumor from cancer stem cells [21, 22]. Often the bulk of the tumor is differ-
entiated, though there is variability in molecular expression patterns and some cells are more
undifferentiated or “stem-like”. To determine the effect of UNC2025 on stem-like cancer cells,
the impact of treatment with UNC2025 on neurosphere formation was determined. Spheres
were developed for ~72 hours and treated with UNC2025 (50nM, 100nM, 200nM, 400nM) or
vehicle for an additional 48hrs, then the diameter of nine random neurospheres per treatment
group was determined and the mean was calculated. Neurospheres derived from the SF188 and
U251 cell lines had a significantly reduced diameter in the presence of 400nMUNC2025 (Fig
2E). The A172 cell line did not readily form neurospheres; therefore the assay was not per-
formed with this cell line.
UNC2025 reduces proliferation and induces polyploidy in glioblastoma
cells
While it was clear that UNC2025 reduced cell number, it was unclear whether UNC2025
affected proliferation, cell death, or both. The amount of BrdU incorporation significantly
decreased following UNC2025 treatment, indicating decreased proliferation in SF188 and
UNC2025 Induces Cell Death, Polyploidy, and Senescence in GBM
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Fig 1. High levels of GAS6 expression correlate with poor prognosis in GBM. GBM samples from the
TCGA data base were divided into quartiles based on GAS6 transcript levels and samples with low (bottom
quartile), moderate (middle quartiles) and high (top quartile) GAS6 expression were defined. A) Kaplan-
Meier curves showing overall survival of GBM patients as a function of GAS6 expression. B) Statistically
significant differences were determined using the log rank test and Tukey’s studentized range test was used
to adjust for multiple comparisons. Hazard ratios were calculated using Cox proportional-hazards model and
the low expression category as the reference.
doi:10.1371/journal.pone.0165107.g001
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Fig 2. UNC2025 inhibits phosphorylation of MERTK in GBM cells leading to reduced cell number, colony-forming
potential, and neurosphere diameter. (A-B) GBM cell lines A172, SF188, and U251, were treated with UNC2025 (50nM, 100nM,
200nM), 200nM UNC2369 (a negative control TKI with similar structure to UNC2025 but lacking MERTK inhibitory activity), or
vehicle (DMSO) for one hour. MERTK protein was immunoprecipitated from cell lysates and phosphorylated MERTK protein was
detected by immunoblot. (A) Representative images from three independent experiments are shown. (B) Phosphorylated and total
UNC2025 Induces Cell Death, Polyploidy, and Senescence in GBM
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U251 cells, while only a trend of decreased proliferation was observed in A172 (Fig 3A and
3B). Additionally, propidium iodide staining, a marker of DNA content, demonstrated a signif-
icant population of UNC2025-treated cells with8N DNA content (Fig 3C and 3D, S1A
Table). Furthermore, in the population of cells that were not polyploid, there was a significant
reduction in G0/G1 phase cells and an increase in G2/M phase (Fig 3E, S1B Table). To confirm
increasedDNA content in cells treated with the highest dose of UNC2025, metaphase spread
was performed on the U251 cell line. As expected, both the untreated and vehicle-treated cells
had approximately 4N DNA content (Fig 3F). In contrast, over half of the UNC2025-treated
cells had8N DNA content (Fig 3F). To further confirm reducedmitotic activity after expo-
sure to UNC2025, phosphorylatedHistone H3 (pHH3), a marker of mitosis, was determined.
U251 cells exposed to UNC2025 had reduced levels of pHH3 compared to the vehicle control
(Fig 3G).
UNC2025 induces cell death in glioblastoma cells
Prolonged mitotic arrest can induce polyploidy and DNA damage, followed by cell cycle arrest
and/or cell death [23]. We have previously shown increased apoptotic cell death, indicated by
increased PARP cleavage, in response to shRNA-mediated inhibition of MerTK [7]. To deter-
mine whether UNC2025 mediates similar effects, cell membrane disruption was determined as
an indicator of cell death. During cellular apoptosis, increasedmembrane permeability can be
detected by assessing infiltration of fluorescent dyes via flow cytometry. Po-Pro-1 is a small dye
that can enter the cell during early apoptosis while propidium iodide, a slightly larger dye, is
excluded until later stages of cell death. After 72 hours of UNC2025 exposure, A172, SF188,
and U251 cells exhibited statistically significant and dose-dependent increases in the fraction
of apoptotic and dead cells (Fig 4A and 4B). At the highest dose (200nM) approximately 80%
of A172 and SF188 cells and 60% of U251 cells were dead or dying. PARP cleavage, a marker of
apoptosis, was also increased in A172 cells and correlated with induction of cell death (S2 Fig).
Similarly, treatment with UNC2025 resulted in reduced levels of Survivin, a protein that is
downstream of MERTK and functions to inhibit apoptosis (S2 Fig).
UNC2025 induces cellular senescence in glioblastoma cells
Visualization of GBM cells after treatment with UNC2025 revealedmorphologic abnormali-
ties. Specifically, the surviving adherent cells had a flattened appearance and demonstrated
increased cell size and nuclear diameter (Fig 5A). Additionally, the cells appeared to have
increased vacuolization. Taken together, these phenotypes are often indicators of cellular
senescence [24]. Consistent with this possibility, treatment of A172, SF188, and U251 cells
with UNC2025 induced beta-galactosidaseactivity (blue staining), a prominent marker of
senescence.[25] (Fig 5B and 5C). Beta-galactosidaseactivity was induced in a dose dependent
manner, with almost 100% of cells exhibiting beta-galactosidasestaining after five days of treat-
ment with the highest dose (200nM) of UNC2025. At a molecular level, p16 and p21 are mark-
ers of senescence [24]. GBM cells often have mutations or deletions of cyclin dependent kinase
MERTK were quantified by densitometry. Mean values and standard errors derived from 3 independent experiments are shown. (C)
GBM cell lines were treated with UNC2025 (50nM, 100nM, 200nM) or vehicle (DMSO) for five days and viable cells were counted
using trypan blue exclusion. Mean values and standard errors were derived from three independent experiments. (D) GBM cultures
were treated with UNC2025 (50nM or 100nM) or vehicle (DMSO) for nine days. Colonies were fixed and stained with 0.5% crystal
violet and counted. Mean values and standard errors were derived from six independent experiments. (E) Neurospheres were
established for 48 hours and then treated with UNC2025 (50nM, 100nM, 200nM, 400nM) or vehicle (DMSO) for 48 hours. Nine
random neurosphere diameters were measured in each well and mean values and standard errors were determined from three
independent experiments. (* p<0.5, ** p<0.01, *** p<0.001, 1-sided ANOVA).
doi:10.1371/journal.pone.0165107.g002
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Fig 3. UNC2025 inhibits proliferation and induces polyploidy in GBM cells. A172, SF188, and U251 cells were treated with
the indicated concentrations of UNC2025, 200nM UNC2369 (a negative control TKI), or vehicle (DMSO) for 48 hours. (A-C) BrdU
was added to the culture medium four hours prior to harvest and cells were fixed, and stained with a fluorescent anti-BrdU antibody
and propidium iodide, prior to analysis by flow cytometry. (A) Representative flow cytometry plots showing BrdU incorporation in the
U251 cell line. (B) Quantitation of BrdU incorporation. Mean values and standard errors derived from 3 independent experiments
UNC2025 Induces Cell Death, Polyploidy, and Senescence in GBM
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inhibitor 2A (CDKN2A), the gene that encodes p16 and p14. Both the U251 and A172 cell
lines have mutated CDKN2A; therefore, p21 expression was investigated as a molecularmarker
of senescence. Although p21 inductionmay result from activation of numerous different intra-
cellular pathways, it is best-characterizeddownstream of p53 so we utilized the A172 cell
line, which has wild-type p53, for these studies [24, 26, 27]. Indeed, p21 protein levels were
increased in A172 cells upon exposure to UNC2025 (Fig 5D). Similarly, senescence-associated
secretory factors IL-6 and IL-8 [28], which are known to be elevated in glioblastoma cells
undergoing senescence [29], were significantly elevated by two to three-fold in the A172 and/
or U251 cell lines (S3 Fig). A similar trend was observed in SF188 cells.
Cells that have undergone a transient cell cycle arrest may recover and resume proliferation
after removal of the initiating stimulus. In contrast, senescence is a stable phenotype and senes-
cent cells do not recover after the initiating treatment is removed [30]. To determine whether
the proliferative phenotype observed in GBM cells treated with UNC2025 is reversible, cell cul-
tures were treated with UNC2025 for five days and then the drug was removed and replaced
with fresh medium either with or without UNC2025 and expansion of the cells in culture was
are shown. (C) Representative flow cytometry plots showing propidium iodide staining as an indicator of DNA content in the U251
cell line. (D-E) Cells were permeabilized and stained with propidium iodide prior to analysis by flow cytometry. (D) Quantitation of
DNA content. Mean values and standard errors derived from four independent experiments are shown. (E) Cell cycle distribution in
cells with <8N DNA content. Mean values and standard errors derived from four independent experiments are shown. (F)
Metaphase spreads were prepared from U251 cells to determine ploidy. Representative images are shown. (G) Cell lysates were
prepared from U251 cells and phosphorylated and total histone H3 (HH3) were detected by immunoblot A representative image
from three independent experiments is shown. (* p<0.5, ** p<0.01, *** p<0.001, 1-sided ANOVA).
doi:10.1371/journal.pone.0165107.g003
Fig 4. UNC2025 induces cell death in GBM cells. A172, SF188, and U251 cells were treated with UNC2025 (50nM, 100nM, 200nM),
control TKI UNC2369 (200nM), or vehicle (DMSO) for 72 hours. Cells were stained with Po-Pro-1 and propidium iodide and analyzed by flow
cytometry to determine apoptotic (Po-Pro-1+/PI-) and dead (PI+) cells. (A) Representative U251 flow cytometry profiles. (B) Mean values and
standard errors derived from three independent experiments. (* p<0.5, ** p<0.01, *** p<0.001, 1-sided ANOVA).
doi:10.1371/journal.pone.0165107.g004
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Fig 5. UNC2025 induces cellular senescence in GBM cells. A172, SF188, and U251 cells were treated with the indicated
concentrations of UNC2025, UNC2369 control TKI (200nM), or vehicle (DMSO). (A) GBM cells treated with UNC2025 exhibit an altered
morphology compared to vehicle (DMSO) treated cells. Representative images from three independent experiments are shown. (B-C)
Cells were treated for five days, then fixed and stained to determine beta-galactosidase activity (blue staining = positive).
Representative images of the A172 cell line (B) and mean values and standard errors derived from four independent experiments for all
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assessed after an additional seven days (day12 of the experiment) (Fig 5E). Cells exposed to
UNC2025 reveal no statistical difference after recovery for seven days in fresh mediumwithout
UNC2025 treatment compared to cells continually exposed to UNC2025 (Fig 5F) which is con-
sistent with a senescent phenotype.
Inhibition of Aurora Kinase B (AURKB) phosphorylation and activation has previously
been associated with both senescent and polyploid phenotypes [31]. UNC2025 inhibits
AURKB in enzymatic assays, although with relatively low potency (IC50 = 8.88nM versus
0.46nM for MERTK) [15]. To investigate whether induction of senescence and polyploidy in
response to treatment with UNC2025 could be mediated by off-target inhibition of AURKB,
GBM cells were treated with UNC2025 and phosphorylation of AURKB was assessed by
immunoblot. UNC2025 did not inhibit phosphorylation of AURKB at concentrations suffi-
cient to induce senescence (Fig 5 and S4 Fig).
MERTK protein levels are increased after cytotoxic therapy
GBM patients receive temozolomide and radiation (up to 56Gy) as standard therapy.[2] Inter-
estingly, MERTK protein levels were increased in a dose dependent manner in SF188 and
U251 cell lines following treatment with cesium source radiation (Fig 6A and S5A Fig). In
contrast, MERTK expression was not induced in A172 cells. Similarly, immunoblot analysis
revealed a trend toward increasedMERTK protein levels in all 3 cell lines following exposure
to chemotherapies, including lomustine (CCNU), cisplatin (CISP), and temozolomide (TMZ)
(Fig 6B and S5B Fig). Significant increases in MERTK expression were confirmed using flow
cytometry to detectMERTK on the surface of SF188 cells treated with cytotoxic chemothera-
pies (Fig 6C and 6D). AXL and TYRO-3, the other members of the TAM family, did not show
any discernable increase after exposure to cytotoxic therapies or radiation (Fig 6A and 6B).
The up-regulation of MERTK after exposure to traditional GBM therapies suggests that
combination therapy might have improved therapeutic effects compared to UNC2025 alone.
Consistent with this idea, we previously demonstrated increased chemosensitivity in G12 and
A172 GBM cells when transduced with shRNA targetingMERTK [7]. Similarly, GBM cells
treated with a combination of UNC2025 and a DNA damaging chemotherapy that is currently
used to treat GBM (CCNUor temozolomide) exhibited an additive reduction in colony forma-
tion relative to either single agent (Fig 7 and S6 Fig).
Discussion
Patients with glioblastoma currently suffer a dismal median survival of ~14 months, with only
26% survival at two years [1]. New therapies are needed: novel drugs that decrease tumor cell
number by inhibiting proliferation and/or inducing apoptosis. MERTK is expressed in>90%
of GBM patient samples, implicating it as a potential target for therapy. Here, we demonstrate
decreased survival associated with high levels of GAS6 expression in GBM, highlighting the
importance of TAM kinase signaling in GBM tumorigenesis and/or therapy resistance and pro-
viding strong rationale for targeting these pathways in the clinic. Treatment with UNC2025, a
novel small molecule inhibitor that potently targets the MERTK ATP binding pocket, reduced
three cell lines (C) are shown. (D) A172 cells were treated for 72 hours and p21 protein, a senescence marker, was detected in cell
lysates by immunoblot. Representative images from three independent experiments are shown. (E) Schematic of experiment
performed in (F). (F) Cells were treated for five days, then media were replaced with fresh medium with or without UNC2025 and cells
were cultured for an additional seven days. Viable cells were counted by trypan blue exclusion on days five and twelve. Mean values
and standard errors were derived from four independent experiments, statistical analysis revealed no difference between continual
drug and drug recovery. (*p<0.5, **p<0.01, ***p<0.001, 1-sided ANOVA).
doi:10.1371/journal.pone.0165107.g005
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phosphorylation (activation) in GBM cell lines. Previous studies demonstrated reduced tumor
cell viability and tumor growth in response to inhibition of MERTK using shRNA or a
MERTK specific antibody [7, 12, 33]. Here we show similar effectsmediated by UNC2025. In
GBM cell lines, UNC2025 treatment reduced tumor cell number, colony forming potential,
neurosphere diameter, proliferation, and viability, suggesting the utility of UNC2025 as a trans-
lational agent and its potential for clinical application.
Fig 6. MerTK expression is increased in GBM cells after treatment with radiation and chemotherapy. A172, SF188, and U251 cells
were exposed to 50uM lomustine (CCNU), 25uM Cisplatin (CISP), or 250uM Temozolomide (TMZ) (A) or radiation (0Gy, 2Gy, 6Gy, 12Gy) (B)
for 48 hours and MERTK, AXL, TYRO3 and tubulin were detected in cell lysates by immunoblot. Representative images from three
independent experiments are shown. (C-D) SF188 cells were treated with 50uM lomustine (CCNU), 25uM Cisplatin (CISP), or 250uM
Temozolomide (TMZ) as described above and MERTK expression was determined by flow cytometry (colors on the flow cytometry graph; light
grey = secondary only; grey = control; black = treatment). Representative images (C) and mean fluorescence intensities (+/- standard error) (D)
from 2–4 independent experiments are shown. (* p<0.5, ** p<0.01, *** p<0.001, 1-sided ANOVA).
doi:10.1371/journal.pone.0165107.g006
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While UNC2025 induced phenotypes consistent with genetic inhibition of MERTK, upon
closer observationwe found that exposure to UNC2025 resulted in induction of polyploidy,
likely due to endo-reduplication.Mitotic arrest and endo-reduplication creates a highly
stressed environment and could be one of the mechanisms leading to induction of cell death in
treated cells. Survivin, an anti-apoptotic and pro-proliferative protein, is highly expressed in
Fig 7. Treatment with UNC2025 in combination with standard GBM chemotherapy is more effective than single agents. A172 cells were
incubated for 9 days with UNC2025 or vehicle (DMSO) combined with either lomustine (CCNU) or temozolomide (TMZ). Colonies were fixed and
stained with crystal violet in 25% methanol and then counted. (A) Mean values derived from four independent experiments. (B-C) The expected
frequency of affect (Fa) for an additive interaction was determined using the Bliss additivity model [32] and is shown (Additive). Statistically significant
(p value < 0.05, student’s paired t test) increases in the observed Fa mediated by UNC2025 plus chemotherapy (Combination) relative to the values
expected for an additive interaction were not observed, indicating additive interactions. (B) Analysis of interactions between UNC2025 and TMZ. (C)
Analysis of interactions between UNC2025 and CCNU.
doi:10.1371/journal.pone.0165107.g007
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GBM cells. Previous work from our lab and work shown here demonstrated regulation of sur-
vivin protein levels downstream of MERTK in non-small cell lung cancer cells and a reduction
in survivin protein in tumor cells treated with UNC2025, including the GBM cell lines U251
and A172 (S5 Fig) [16, 33]. GBMs are known to have chromosomal instability and survivin
inhibition in GBM cells results in polyploidy and enlarged cellular size [34]. Survivin forms a
complex with aurora kinase B (AURKB) to mediate mitotic spindle assembly checkpoint and
cytokinesis functions [35]. Interestingly, while inhibition of Survivin and significant induction
of polyploidy were evident at concentrations of UNC2025 as low as 100nM, AURKB phos-
phorylation was not affected. Taken together, these observations demonstrate induction of
polyploidy independent of AURKB inhibition and implicate reduction in survivin in response
to treatment with UNC2025 as a mediator of the pleiotropic mitotic defects we observedhere,
including polyploidy or endo-reduplication and aberrant mitotic spindle formation leading to
non-uniform endo-reduplication and eventually to cell death or cellular senescence. In accor-
dance with our findings, previous studies showed that survivin inhibition using RNAi or a
pharmacologic agent, YM155, in GBM cell lines was sufficient to induce polyploidy and cell
death [36, 37]. Induction of polyploidy in response to MERTK inhibition is a novel finding and
reveals a newmechanism by which therapeutic agents targetingMERTK may mediate anti-
tumor activity in GBM cells.
Similarly, UNC2025 induces a senescent phenotype in the majority of surviving cells, poten-
tially involving dysregulation of the same AURKB and survivin complex. Previous studies
demonstrated induction of a senescent morphology in response to AURKB inhibition [31]. As
for the polyploid phenotype, induction of senescence in our studies was independent of
AURKB inhibition, suggesting an alternate mechanism for the observedphenotypes. For
instance, decreased survivin levels could prevent efficient formation of the survivin/AURKB/
INCENP complex, thereby inhibiting nuclear division and cytokinesis independent of any
impact on AURKB activity.
We observedhigherMERTK protein levels in GBM cell lines in response to treatment with
chemotherapy. This observation is consistent with previous data demonstrating increased sen-
sitivity to chemotherapy in GBM cells in response to shRNA-mediated MERTK inhibition and
suggests a mechanism by which upregulation of MERTK activates pro-survival signaling path-
ways to promote chemoresistance. The increase in MERTK could reflect upregulation of the
protein in response to chemotherapy treatment to promote tumor cell survival or selective sur-
vival of cells expressing higher levels of MERTK protein, providing rationale for MERTK inhi-
bition in combination with cytotoxic chemotherapy for treatment of GBM. Combination
therapy is likely to yield the most efficacious results, since single agent therapies have been of
little success in patients with GBM thus far. Consistent with this idea, combined treatment
with UNC2025 and standard chemotherapies resulted in more efficient inhibition of colony
formation relative to single agent therapies.
In summary, MERTK, a transmembrane tyrosine kinase, is overexpressed in GBM cells
compared to normal brain tissue, and signals through survival and proliferative pathways.
Expression of GAS6, a MERTK ligand, portends poor prognosis, indicating the importance of
TAM kinase signaling in patients with GBM. Specific inhibition of MERTK by UNC2025, a
small molecule tyrosine kinase inhibitor, reducedGBM cell viability, proliferation, colony-
forming potential, and neurosphere diameter and induced polyploidy and senescence. The
molecular pathways that are regulated downstream of MERTK inhibition following treatment
with UNC2025 to mediate these effects in GBM cells remain to be further elucidated, but the
data presented here implicate UNC2025 as a potential therapeutic for treatment of GBM as a
monotherapy or in combination with standard therapy.
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Supporting Information
S1 Table. Statistical analysis of cell cycle distribution and DNA content in GBM cultures
treated with UNC2025, UNC2369, or vehicle.A172, SF188, and U251 were cultured with
UNC2025, UNC2369 or DMSO vehicle for 48 hours, then stained with Pro-Po-1 and propi-
dium iodide and analyzed by flow cytometry. (A) Percentages of cells with 2N, 4N, and8N
DNA content, determined by 7-AAD staining. (B) Percentages of cycling cells in G0/G1, S, and
G2/M phases of the cell cycle were determined based on DNA content indicated by 7-AAD
staining. Polyploid cells containing>4N DNA content were excluded from the analysis. Mean
values and standard errors were derived from 3 independent experiments. Statistical differ-
ences relative to vehicle-treated cultures were determined using 1-sided ANOVA.
(TIF)
S1 Fig. Pairwise correlative analysis of AXL, MERTK, and GAS6 transcripts in GBM
patient samples. Scatter plots showing significant correlations between expression of MERTK
and AXL (left panel), MERTK and GAS6 (middle panel), and AXL and GAS6 (right panel) in
GBM patient samples from the TCGA database.
(TIF)
S2 Fig. UNC2025 induces PARP cleavage and decreasesSurvivin expression in GBM cells.
A172 cells were cultured with UNC2025 (50nM, 100nM, and 200nM) for 24 (top panels) or 48
(bottom panels) hours. Whole cell lysates were prepared and the indicated proteins were
detected by immunoblot. Images are representative of two independent experiments.
(FL = Full length).
(TIF)
S3 Fig. UNC2025 increases senescence-associatedsecretory factors IL-6 and IL-8 in glio-
blastoma cell cultures.The A172, SF188, and U251 cell lines were cultured with 200nM
UNC2025 for 5 days, then media was collected and IL-6 and IL-8 proteins were quantitated by
ELISA.Mean values and standard errors derived from 3 independent experiments are shown.
(p<0.05, p<0.01, 1-sided ANOVA)
(TIF)
S4 Fig. UNC2025 does not inhibit AURKB at concentrations sufficient to induce senes-
cence in GBM cells.A172 cells were treated with UNC2025 or vehicle for one hour and lysates
were prepared. Phosphorylated (denoted by p) and total Aurora Kinase B were detected by
immunoblot. Tubulin is shown as a loading control. Images are representative of two indepen-
dent experiments.
(TIF)
S5 Fig. Chemotherapyand radiation increase total MERTK protein levels.Densitometry
was used to quantitate immunoblots derived from cells treated with radiation (A) or cytotoxic
chemotherapy (B) as depicted in Fig 6. Mean values and standard errors derived from 2–4
independent experiments are shown. (p<0.01, 1-sided ANOVA)
(TIF)
S6 Fig. UNC2025 Exhibits Additive Interactions with Temozolomide and Lomustine in
GlioblastomaCell Lines. SF188 (A-C) and U251 (D-F) were cultured with UNC2025 and/or
temozolomide or lomustine (CCNU) for 9 days. Colonies were fixed and stained with crystal
violet in methanol, then counted. The expected frequency of affect (Fa) for an additive interac-
tion was determined using the Bliss additivity model [32] and is shown (Additive). Statistically
significant (p value< 0.05, student’s paired t test) increases in the observedFa mediated by
UNC2025 Induces Cell Death, Polyploidy, and Senescence in GBM
PLOS ONE | DOI:10.1371/journal.pone.0165107 October 26, 2016 17 / 20
UNC2025 plus chemotherapy (Combination) relative to the values expected for an additive
interaction were not observed, indicating additive interactions. Mean values and standard
errors were derived from 4–6 independent experiments.
(TIF)
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